List view / Grid view
Drs Sam Cooper and Michael Briskin of Phenomic AI, discuss how artificial intelligence (AI) is enabling them to target multi-cellular interactions, such as those in the tumour stroma, for drug development.
Discover how workflows are being accelerated to speed up the vaccine research and development process while maintaining safety and immunogenicity.
Computational drug screening has shown that chemotherapy drug pralatrexate could potentially be repurposed to treat COVID-19.
Dr Isaac Karimi and his team explain how compounds to treat COVID-19 could be found in Kurdish ethnomedicine, selecting some plants for computational drug discovery.
Scientists have created a drug discovery platform that enables the discovery and optimisation of RNA-targeting compounds.
Scientists have trained a computer algorithm to identify differences in cancer cell lines based on microscopic images, preventing the misclassification of cells.
Dr Diogo Camacho from the Wyss Institute at Harvard discusses new research into using machine learning algorithms to analyse RNA sequences and reveal potential drug targets.
Researchers at Ingenza and the University of Plymouth are using a machine learning and high‑throughput screening approach to discover novel antimicrobial therapies. In this article, Nikki Withers spoke to one of the researchers, Jack Kay, to hear about the current threat posed by antimicrobial resistance and how he hopes their…
An artificial intelligence (AI) system called AlphaFold has been developed to effectively predict protein structures and folding.
A model of a human lung cell has been used to understand how SARS-CoV-2 uses host cell processes to reproduce, revealing drug targets.
In this in-depth focus find out how genetic screening can be used to customise healthcare and why scientists have turned to machine learning in the fight against antimicrobial resistance.
In this journal, find articles discussing antimicrobial resistance, exploring why inhibiting the interaction between SARS-CoV-2 and neuropilin-1 could help combat COVID-19, as well as how CRISPR can be used to enhance productivity in cell line development. Also in this issue, features on engineering new biologic drugs and precision medicine.
UKRI will provide £4 million in funding to establish a data infrastructure for scientists in the UK to study antibodies from COVID-19 patient samples.
The tool uses interactive molecular dynamics simulations in virtual reality (iMD-VR) to allow researchers to step inside SARS-CoV-2 enzymes and visualise molecules binding to them.
![robotic hand pipetting from petri dish of organoids next to a clock - idea of automation speeding up organoid development [Credit: Daria Sokol/MIPT Press Office].](https://www.drugtargetreview.com/wp-content/uploads/algorithm-accelerating-organoid-development.jpg)
The semi-automated process enabled researchers to make retinal organoid production and selection nearly four times faster.
